 | • レポートコード：GIR-107A12008 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、α1アドレナリン作動薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。α1アドレナリン作動薬の種類別市場規模（フェニレフリン、メトキサミン、ミドドリン、オキシメタゾリン）、用途別市場規模（発作性上室性頻拍、点眼薬、アナフィラキシー、心停止、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・α1アドレナリン作動薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bausch Health Companies、Pfizer、Sterling Winthrop、Sanofi、Paragon BioTeck、West-Ward Pharmaceuticals 、Biosyent Pharma 、Novartis、Omega Laboratories、Medical Purchasing Solutions、Avadel Legacy Pharmaceuticals、Amneal Biosciences、Cipla USA、Par Pharmaceutical、Glaxosmithkline、Teva、Bayer、Impax Generics、Mylan Pharmaceuticals、Physicians Total Care、Merck ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：フェニレフリン、メトキサミン、ミドドリン、オキシメタゾリン ・用途別分析2016年-2026年：発作性上室性頻拍、点眼薬、アナフィラキシー、心停止、その他 ・α1アドレナリン作動薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・α1アドレナリン作動薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・α1アドレナリン作動薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・α1アドレナリン作動薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・α1アドレナリン作動薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The α1 Adrenergic Agonist market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global α1 Adrenergic Agonist size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global α1 Adrenergic Agonist market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
α1 Adrenergic Agonist market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Phenylephrine
Methoxamine
Midodrine
Oxymetazoline
Market segment by Application, can be divided into
Paroxysmal Supraventricular Tachycardia
Eye Drops
Anaphylaxis
Cardiac Arrest
Anaphylaxis
Cardiac Arrest
Others
Market segment by players, this report covers
Bausch Health Companies
Pfizer
Sterling Winthrop
Sanofi
Paragon BioTeck
West-Ward Pharmaceuticals
Biosyent Pharma
Novartis
Omega Laboratories
Medical Purchasing Solutions
Avadel Legacy Pharmaceuticals
Amneal Biosciences
Cipla USA
Par Pharmaceutical
Glaxosmithkline
Teva
Bayer
Impax Generics
Mylan Pharmaceuticals
Physicians Total Care
Merck
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of α1 Adrenergic Agonist
1.2 Classification of α1 Adrenergic Agonist by Type
1.2.1 Overview: Global α1 Adrenergic Agonist Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global α1 Adrenergic Agonist Revenue Market Share by Type in 2020
1.2.3 Phenylephrine
1.2.4 Methoxamine
1.2.5 Midodrine
1.2.6 Oxymetazoline
1.3 Global α1 Adrenergic Agonist Market by Application
1.3.1 Overview: Global α1 Adrenergic Agonist Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Paroxysmal Supraventricular Tachycardia
1.3.3 Eye Drops
1.3.4 Anaphylaxis
1.3.5 Cardiac Arrest
1.3.6 Anaphylaxis
1.3.7 Cardiac Arrest
1.3.8 Others
1.4 Global α1 Adrenergic Agonist Market Size & Forecast
1.5 Global α1 Adrenergic Agonist Market Size and Forecast by Region
1.5.1 Global α1 Adrenergic Agonist Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global α1 Adrenergic Agonist Market Size by Region, (2016-2021)
1.5.3 North America α1 Adrenergic Agonist Market Size and Prospect (2016-2026)
1.5.4 Europe α1 Adrenergic Agonist Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific α1 Adrenergic Agonist Market Size and Prospect (2016-2026)
1.5.6 South America α1 Adrenergic Agonist Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa α1 Adrenergic Agonist Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 α1 Adrenergic Agonist Market Drivers
1.6.2 α1 Adrenergic Agonist Market Restraints
1.6.3 α1 Adrenergic Agonist Trends Analysis
2 Company Profiles
2.1 Bausch Health Companies
2.1.1 Bausch Health Companies Details
2.1.2 Bausch Health Companies Major Business
2.1.3 Bausch Health Companies α1 Adrenergic Agonist Product and Solutions
2.1.4 Bausch Health Companies α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bausch Health Companies Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer α1 Adrenergic Agonist Product and Solutions
2.2.4 Pfizer α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Sterling Winthrop
2.3.1 Sterling Winthrop Details
2.3.2 Sterling Winthrop Major Business
2.3.3 Sterling Winthrop α1 Adrenergic Agonist Product and Solutions
2.3.4 Sterling Winthrop α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Sterling Winthrop Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi α1 Adrenergic Agonist Product and Solutions
2.4.4 Sanofi α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Paragon BioTeck
2.5.1 Paragon BioTeck Details
2.5.2 Paragon BioTeck Major Business
2.5.3 Paragon BioTeck α1 Adrenergic Agonist Product and Solutions
2.5.4 Paragon BioTeck α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Paragon BioTeck Recent Developments and Future Plans
2.6 West-Ward Pharmaceuticals
2.6.1 West-Ward Pharmaceuticals Details
2.6.2 West-Ward Pharmaceuticals Major Business
2.6.3 West-Ward Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
2.6.4 West-Ward Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 West-Ward Pharmaceuticals Recent Developments and Future Plans
2.7 Biosyent Pharma
2.7.1 Biosyent Pharma Details
2.7.2 Biosyent Pharma Major Business
2.7.3 Biosyent Pharma α1 Adrenergic Agonist Product and Solutions
2.7.4 Biosyent Pharma α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Biosyent Pharma Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis α1 Adrenergic Agonist Product and Solutions
2.8.4 Novartis α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Omega Laboratories
2.9.1 Omega Laboratories Details
2.9.2 Omega Laboratories Major Business
2.9.3 Omega Laboratories α1 Adrenergic Agonist Product and Solutions
2.9.4 Omega Laboratories α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Omega Laboratories Recent Developments and Future Plans
2.10 Medical Purchasing Solutions
2.10.1 Medical Purchasing Solutions Details
2.10.2 Medical Purchasing Solutions Major Business
2.10.3 Medical Purchasing Solutions α1 Adrenergic Agonist Product and Solutions
2.10.4 Medical Purchasing Solutions α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Medical Purchasing Solutions Recent Developments and Future Plans
2.11 Avadel Legacy Pharmaceuticals
2.11.1 Avadel Legacy Pharmaceuticals Details
2.11.2 Avadel Legacy Pharmaceuticals Major Business
2.11.3 Avadel Legacy Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
2.11.4 Avadel Legacy Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Avadel Legacy Pharmaceuticals Recent Developments and Future Plans
2.12 Amneal Biosciences
2.12.1 Amneal Biosciences Details
2.12.2 Amneal Biosciences Major Business
2.12.3 Amneal Biosciences α1 Adrenergic Agonist Product and Solutions
2.12.4 Amneal Biosciences α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Amneal Biosciences Recent Developments and Future Plans
2.13 Cipla USA
2.13.1 Cipla USA Details
2.13.2 Cipla USA Major Business
2.13.3 Cipla USA α1 Adrenergic Agonist Product and Solutions
2.13.4 Cipla USA α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Cipla USA Recent Developments and Future Plans
2.14 Par Pharmaceutical
2.14.1 Par Pharmaceutical Details
2.14.2 Par Pharmaceutical Major Business
2.14.3 Par Pharmaceutical α1 Adrenergic Agonist Product and Solutions
2.14.4 Par Pharmaceutical α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Par Pharmaceutical Recent Developments and Future Plans
2.15 Glaxosmithkline
2.15.1 Glaxosmithkline Details
2.15.2 Glaxosmithkline Major Business
2.15.3 Glaxosmithkline α1 Adrenergic Agonist Product and Solutions
2.15.4 Glaxosmithkline α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Glaxosmithkline Recent Developments and Future Plans
2.16 Teva
2.16.1 Teva Details
2.16.2 Teva Major Business
2.16.3 Teva α1 Adrenergic Agonist Product and Solutions
2.16.4 Teva α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Teva Recent Developments and Future Plans
2.17 Bayer
2.17.1 Bayer Details
2.17.2 Bayer Major Business
2.17.3 Bayer α1 Adrenergic Agonist Product and Solutions
2.17.4 Bayer α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Bayer Recent Developments and Future Plans
2.18 Impax Generics
2.18.1 Impax Generics Details
2.18.2 Impax Generics Major Business
2.18.3 Impax Generics α1 Adrenergic Agonist Product and Solutions
2.18.4 Impax Generics α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Impax Generics Recent Developments and Future Plans
2.19 Mylan Pharmaceuticals
2.19.1 Mylan Pharmaceuticals Details
2.19.2 Mylan Pharmaceuticals Major Business
2.19.3 Mylan Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
2.19.4 Mylan Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Mylan Pharmaceuticals Recent Developments and Future Plans
2.20 Physicians Total Care
2.20.1 Physicians Total Care Details
2.20.2 Physicians Total Care Major Business
2.20.3 Physicians Total Care α1 Adrenergic Agonist Product and Solutions
2.20.4 Physicians Total Care α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Physicians Total Care Recent Developments and Future Plans
2.21 Merck
2.21.1 Merck Details
2.21.2 Merck Major Business
2.21.3 Merck α1 Adrenergic Agonist Product and Solutions
2.21.4 Merck α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Merck Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global α1 Adrenergic Agonist Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 α1 Adrenergic Agonist Players Market Share
3.2.2 Top 10 α1 Adrenergic Agonist Players Market Share
3.2.3 Market Competition Trend
3.3 α1 Adrenergic Agonist Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global α1 Adrenergic Agonist Revenue and Market Share by Type (2016-2021)
4.2 Global α1 Adrenergic Agonist Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global α1 Adrenergic Agonist Revenue Market Share by Application (2016-2021)
5.2 α1 Adrenergic Agonist Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America α1 Adrenergic Agonist Revenue by Type (2016-2026)
6.2 North America α1 Adrenergic Agonist Revenue by Application (2016-2026)
6.3 North America α1 Adrenergic Agonist Market Size by Country
6.3.1 North America α1 Adrenergic Agonist Revenue by Country (2016-2026)
6.3.2 United States α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
6.3.3 Canada α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
6.3.4 Mexico α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe α1 Adrenergic Agonist Revenue by Type (2016-2026)
7.2 Europe α1 Adrenergic Agonist Revenue by Application (2016-2026)
7.3 Europe α1 Adrenergic Agonist Market Size by Country
7.3.1 Europe α1 Adrenergic Agonist Revenue by Country (2016-2026)
7.3.2 Germany α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
7.3.3 France α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
7.3.4 United Kingdom α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
7.3.5 Russia α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
7.3.6 Italy α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific α1 Adrenergic Agonist Revenue by Type (2016-2026)
8.2 Asia-Pacific α1 Adrenergic Agonist Revenue by Application (2016-2026)
8.3 Asia-Pacific α1 Adrenergic Agonist Market Size by Region
8.3.1 Asia-Pacific α1 Adrenergic Agonist Revenue by Region (2016-2026)
8.3.2 China α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8.3.3 Japan α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8.3.4 South Korea α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8.3.5 India α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
8.3.7 Australia α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America α1 Adrenergic Agonist Revenue by Type (2016-2026)
9.2 South America α1 Adrenergic Agonist Revenue by Application (2016-2026)
9.3 South America α1 Adrenergic Agonist Market Size by Country
9.3.1 South America α1 Adrenergic Agonist Revenue by Country (2016-2026)
9.3.2 Brazil α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
9.3.3 Argentina α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa α1 Adrenergic Agonist Revenue by Type (2016-2026)
10.2 Middle East & Africa α1 Adrenergic Agonist Revenue by Application (2016-2026)
10.3 Middle East & Africa α1 Adrenergic Agonist Market Size by Country
10.3.1 Middle East & Africa α1 Adrenergic Agonist Revenue by Country (2016-2026)
10.3.2 Turkey α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
10.3.4 UAE α1 Adrenergic Agonist Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global α1 Adrenergic Agonist Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global α1 Adrenergic Agonist Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market α1 Adrenergic Agonist Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global α1 Adrenergic Agonist Revenue (USD Million) by Region (2016-2021)
Table 5. Global α1 Adrenergic Agonist Revenue Market Share by Region (2021-2026)
Table 6. Bausch Health Companies Corporate Information, Head Office, and Major Competitors
Table 7. Bausch Health Companies Major Business
Table 8. Bausch Health Companies α1 Adrenergic Agonist Product and Solutions
Table 9. Bausch Health Companies α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer α1 Adrenergic Agonist Product and Solutions
Table 13. Pfizer α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Sterling Winthrop Corporate Information, Head Office, and Major Competitors
Table 15. Sterling Winthrop Major Business
Table 16. Sterling Winthrop α1 Adrenergic Agonist Product and Solutions
Table 17. Sterling Winthrop α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Sanofi Corporate Information, Head Office, and Major Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi α1 Adrenergic Agonist Product and Solutions
Table 21. Sanofi α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Paragon BioTeck Corporate Information, Head Office, and Major Competitors
Table 23. Paragon BioTeck Major Business
Table 24. Paragon BioTeck α1 Adrenergic Agonist Product and Solutions
Table 25. Paragon BioTeck α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. West-Ward Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. West-Ward Pharmaceuticals Major Business
Table 28. West-Ward Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
Table 29. West-Ward Pharmaceuticals α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Biosyent Pharma Corporate Information, Head Office, and Major Competitors
Table 31. Biosyent Pharma Major Business
Table 32. Biosyent Pharma α1 Adrenergic Agonist Product and Solutions
Table 33. Biosyent Pharma α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis α1 Adrenergic Agonist Product and Solutions
Table 37. Novartis α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Omega Laboratories Corporate Information, Head Office, and Major Competitors
Table 39. Omega Laboratories Major Business
Table 40. Omega Laboratories α1 Adrenergic Agonist Product and Solutions
Table 41. Omega Laboratories α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Medical Purchasing Solutions Corporate Information, Head Office, and Major Competitors
Table 43. Medical Purchasing Solutions Major Business
Table 44. Medical Purchasing Solutions α1 Adrenergic Agonist Product and Solutions
Table 45. Medical Purchasing Solutions α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Avadel Legacy Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Avadel Legacy Pharmaceuticals Major Business
Table 48. Avadel Legacy Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
Table 49. Avadel Legacy Pharmaceuticals α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Amneal Biosciences Corporate Information, Head Office, and Major Competitors
Table 51. Amneal Biosciences Major Business
Table 52. Amneal Biosciences α1 Adrenergic Agonist Product and Solutions
Table 53. Amneal Biosciences α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Cipla USA Corporate Information, Head Office, and Major Competitors
Table 55. Cipla USA Major Business
Table 56. Cipla USA α1 Adrenergic Agonist Product and Solutions
Table 57. Cipla USA α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Par Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 59. Par Pharmaceutical Major Business
Table 60. Par Pharmaceutical α1 Adrenergic Agonist Product and Solutions
Table 61. Par Pharmaceutical α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Glaxosmithkline Corporate Information, Head Office, and Major Competitors
Table 63. Glaxosmithkline Major Business
Table 64. Glaxosmithkline α1 Adrenergic Agonist Product and Solutions
Table 65. Glaxosmithkline α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Teva Corporate Information, Head Office, and Major Competitors
Table 67. Teva Major Business
Table 68. Teva α1 Adrenergic Agonist Product and Solutions
Table 69. Teva α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Bayer Corporate Information, Head Office, and Major Competitors
Table 71. Bayer Major Business
Table 72. Bayer α1 Adrenergic Agonist Product and Solutions
Table 73. Bayer α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Impax Generics Corporate Information, Head Office, and Major Competitors
Table 75. Impax Generics Major Business
Table 76. Impax Generics α1 Adrenergic Agonist Product and Solutions
Table 77. Impax Generics α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Mylan Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 79. Mylan Pharmaceuticals Major Business
Table 80. Mylan Pharmaceuticals α1 Adrenergic Agonist Product and Solutions
Table 81. Mylan Pharmaceuticals α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Physicians Total Care Corporate Information, Head Office, and Major Competitors
Table 83. Physicians Total Care Major Business
Table 84. Physicians Total Care α1 Adrenergic Agonist Product and Solutions
Table 85. Physicians Total Care α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Merck Corporate Information, Head Office, and Major Competitors
Table 87. Merck Major Business
Table 88. Merck α1 Adrenergic Agonist Product and Solutions
Table 89. Merck α1 Adrenergic Agonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Global α1 Adrenergic Agonist Revenue (USD Million) by Players (2019-2021)
Table 91. Global α1 Adrenergic Agonist Revenue Share by Players (2019-2021)
Table 92. Breakdown of α1 Adrenergic Agonist by Company Type (Tier 1, Tier 2 and Tier 3)
Table 93. α1 Adrenergic Agonist Players Head Office, Products and Services Provided
Table 94. α1 Adrenergic Agonist Mergers & Acquisitions in the Past Five Years
Table 95. α1 Adrenergic Agonist New Entrants and Expansion Plans
Table 96. Global α1 Adrenergic Agonist Revenue (USD Million) by Type (2016-2021)
Table 97. Global α1 Adrenergic Agonist Revenue Share by Type (2016-2021)
Table 98. Global α1 Adrenergic Agonist Revenue Forecast by Type (2021-2026)
Table 99. Global α1 Adrenergic Agonist Revenue by Application (2016-2021)
Table 100. Global α1 Adrenergic Agonist Revenue Forecast by Application (2021-2026)
Table 101. North America α1 Adrenergic Agonist Revenue by Type (2016-2021) & (USD Million)
Table 102. North America α1 Adrenergic Agonist Revenue by Type (2021-2026) & (USD Million)
Table 103. North America α1 Adrenergic Agonist Revenue by Application (2016-2021) & (USD Million)
Table 104. North America α1 Adrenergic Agonist Revenue by Application (2021-2026) & (USD Million)
Table 105. North America α1 Adrenergic Agonist Revenue by Country (2016-2021) & (USD Million)
Table 106. North America α1 Adrenergic Agonist Revenue by Country (2021-2026) & (USD Million)
Table 107. Europe α1 Adrenergic Agonist Revenue by Type (2016-2021) & (USD Million)
Table 108. Europe α1 Adrenergic Agonist Revenue by Type (2021-2026) & (USD Million)
Table 109. Europe α1 Adrenergic Agonist Revenue by Application (2016-2021) & (USD Million)
Table 110. Europe α1 Adrenergic Agonist Revenue by Application (2021-2026) & (USD Million)
Table 111. Europe α1 Adrenergic Agonist Revenue by Country (2016-2021) & (USD Million)
Table 112. Europe α1 Adrenergic Agonist Revenue by Country (2021-2026) & (USD Million)
Table 113. Asia-Pacific α1 Adrenergic Agonist Revenue by Type (2016-2021) & (USD Million)
Table 114. Asia-Pacific α1 Adrenergic Agonist Revenue by Type (2021-2026) & (USD Million)
Table 115. Asia-Pacific α1 Adrenergic Agonist Revenue by Application (2016-2021) & (USD Million)
Table 116. Asia-Pacific α1 Adrenergic Agonist Revenue by Application (2021-2026) & (USD Million)
Table 117. Asia-Pacific α1 Adrenergic Agonist Revenue by Region (2016-2021) & (USD Million)
Table 118. Asia-Pacific α1 Adrenergic Agonist Revenue by Region (2021-2026) & (USD Million)
Table 119. South America α1 Adrenergic Agonist Revenue by Type (2016-2021) & (USD Million)
Table 120. South America α1 Adrenergic Agonist Revenue by Type (2021-2026) & (USD Million)
Table 121. South America α1 Adrenergic Agonist Revenue by Application (2016-2021) & (USD Million)
Table 122. South America α1 Adrenergic Agonist Revenue by Application (2021-2026) & (USD Million)
Table 123. South America α1 Adrenergic Agonist Revenue by Country (2016-2021) & (USD Million)
Table 124. South America α1 Adrenergic Agonist Revenue by Country (2021-2026) & (USD Million)
Table 125. Middle East & Africa α1 Adrenergic Agonist Revenue by Type (2016-2021) & (USD Million)
Table 126. Middle East & Africa α1 Adrenergic Agonist Revenue by Type (2021-2026) & (USD Million)
Table 127. Middle East & Africa α1 Adrenergic Agonist Revenue by Application (2016-2021) & (USD Million)
Table 128. Middle East & Africa α1 Adrenergic Agonist Revenue by Application (2021-2026) & (USD Million)
Table 129. Middle East & Africa α1 Adrenergic Agonist Revenue by Country (2016-2021) & (USD Million)
Table 130. Middle East & Africa α1 Adrenergic Agonist Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. α1 Adrenergic Agonist Picture
Figure 2. Global α1 Adrenergic Agonist Revenue Market Share by Type in 2020
Figure 3. Phenylephrine
Figure 4. Methoxamine
Figure 5. Midodrine
Figure 6. Oxymetazoline
Figure 7. α1 Adrenergic Agonist Revenue Market Share by Application in 2020
Figure 8. Paroxysmal Supraventricular Tachycardia Picture
Figure 9. Eye Drops Picture
Figure 10. Anaphylaxis Picture
Figure 11. Cardiac Arrest Picture
Figure 12. Anaphylaxis Picture
Figure 13. Cardiac Arrest Picture
Figure 14. Others Picture
Figure 15. Global α1 Adrenergic Agonist Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global α1 Adrenergic Agonist Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global α1 Adrenergic Agonist Revenue Market Share by Region (2016-2026)
Figure 18. Global α1 Adrenergic Agonist Revenue Market Share by Region in 2020
Figure 19. North America α1 Adrenergic Agonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe α1 Adrenergic Agonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific α1 Adrenergic Agonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America α1 Adrenergic Agonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa α1 Adrenergic Agonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. α1 Adrenergic Agonist Market Drivers
Figure 25. α1 Adrenergic Agonist Market Restraints
Figure 26. α1 Adrenergic Agonist Market Trends
Figure 27. Bausch Health Companies Recent Developments and Future Plans
Figure 28. Pfizer Recent Developments and Future Plans
Figure 29. Sterling Winthrop Recent Developments and Future Plans
Figure 30. Sanofi Recent Developments and Future Plans
Figure 31. Paragon BioTeck Recent Developments and Future Plans
Figure 32. West-Ward Pharmaceuticals Recent Developments and Future Plans
Figure 33. Biosyent Pharma Recent Developments and Future Plans
Figure 34. Novartis Recent Developments and Future Plans
Figure 35. Omega Laboratories Recent Developments and Future Plans
Figure 36. Medical Purchasing Solutions Recent Developments and Future Plans
Figure 37. Avadel Legacy Pharmaceuticals Recent Developments and Future Plans
Figure 38. Amneal Biosciences Recent Developments and Future Plans
Figure 39. Cipla USA Recent Developments and Future Plans
Figure 40. Par Pharmaceutical Recent Developments and Future Plans
Figure 41. Glaxosmithkline Recent Developments and Future Plans
Figure 42. Teva Recent Developments and Future Plans
Figure 43. Bayer Recent Developments and Future Plans
Figure 44. Impax Generics Recent Developments and Future Plans
Figure 45. Mylan Pharmaceuticals Recent Developments and Future Plans
Figure 46. Physicians Total Care Recent Developments and Future Plans
Figure 47. Merck Recent Developments and Future Plans
Figure 48. Global α1 Adrenergic Agonist Revenue Share by Players in 2020
Figure 49. α1 Adrenergic Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 50. Global Top 3 Players α1 Adrenergic Agonist Revenue Market Share in 2020
Figure 51. Global Top 10 Players α1 Adrenergic Agonist Revenue Market Share in 2020
Figure 52. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 53. Global α1 Adrenergic Agonist Revenue Share by Type in 2020
Figure 54. Global α1 Adrenergic Agonist Market Share Forecast by Type (2021-2026)
Figure 55. Global α1 Adrenergic Agonist Revenue Share by Application in 2020
Figure 56. Global α1 Adrenergic Agonist Market Share Forecast by Application (2021-2026)
Figure 57. North America α1 Adrenergic Agonist Sales Market Share by Type (2016-2026)
Figure 58. North America α1 Adrenergic Agonist Sales Market Share by Application (2016-2026)
Figure 59. North America α1 Adrenergic Agonist Revenue Market Share by Country (2016-2026)
Figure 60. United States α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Canada α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Mexico α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Europe α1 Adrenergic Agonist Sales Market Share by Type (2016-2026)
Figure 64. Europe α1 Adrenergic Agonist Sales Market Share by Application (2016-2026)
Figure 65. Europe α1 Adrenergic Agonist Revenue Market Share by Country (2016-2026)
Figure 66. Germany α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. France α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. United Kingdom α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Russia α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Italy α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Asia-Pacific α1 Adrenergic Agonist Sales Market Share by Type (2016-2026)
Figure 72. Asia-Pacific α1 Adrenergic Agonist Sales Market Share by Application (2016-2026)
Figure 73. Asia-Pacific α1 Adrenergic Agonist Revenue Market Share by Region (2016-2026)
Figure 74. China α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Japan α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South Korea α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. India α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Southeast Asia α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Australia α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. South America α1 Adrenergic Agonist Sales Market Share by Type (2016-2026)
Figure 81. South America α1 Adrenergic Agonist Sales Market Share by Application (2016-2026)
Figure 82. South America α1 Adrenergic Agonist Revenue Market Share by Country (2016-2026)
Figure 83. Brazil α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. Argentina α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Middle East and Africa α1 Adrenergic Agonist Sales Market Share by Type (2016-2026)
Figure 86. Middle East and Africa α1 Adrenergic Agonist Sales Market Share by Application (2016-2026)
Figure 87. Middle East and Africa α1 Adrenergic Agonist Revenue Market Share by Country (2016-2026)
Figure 88. Turkey α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 89. Saudi Arabia α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 90. UAE α1 Adrenergic Agonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. Methodology
Figure 92. Research Process and Data Source
世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場 2021：企業別、地域別、種類・用途別 The Glucagon-like Peptide-2 (GLP-2) Agonist market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…- 世界のGABA受容体アゴニスト薬市場 2021：企業別、地域別、種類・用途別 The GABA Receptor Agonist Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界のメトキサミン市場 2021：企業別、地域別、種類・用途別 The Methoxamine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent…
- 世界の緑内障治療市場予測（～2024年） Glaucoma can be treated with eye drops, pills, laser surgery, traditional surgery or a combination of these methods. The goal of any treatment is to prevent loss of vision, as vision loss from glaucoma is irreversible. Scope of the Report: In the last several years, Hong Kong market of Glaucoma Trea…
- 世界のオキシメタゾリン市場 2021：企業別、地域別、種類・用途別 The Oxymetazoline market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rece…